Goldman Sachs Maintains Buy on Day One Biopharmaceutical, Lowers Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Andrea Tan has maintained a 'Buy' rating on Day One Biopharmaceutical (NASDAQ:DAWN) but lowered the price target from $63 to $54.
August 08, 2023 | 2:22 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs has maintained a 'Buy' rating on Day One Biopharmaceutical but lowered the price target from $63 to $54.
The news is directly related to Day One Biopharmaceutical. While the 'Buy' rating is maintained, the lowering of the price target might indicate a slower growth expectation, which could potentially impact the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100